Search Results

ObsEva SA announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today.

ObsEva SA announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing.

ObsEva SA announced that, following a comprehensive assessment of the company’s financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, published its Half Year 2023 Financial Statements.

ObsEva SA announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange’s listing authority that there was a substantial risk that it will lack the resources to have financial statements for 2023 prepared under IFRS audited, and that it is as a result likely not going to be able to satisfy the requirements for maintaining its listing on SIX.

ObsEva SA announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing embryo transfer after in vitro fertilization, following the termination of its sub-licensing agreement with Yuyuan BioScience.

ObsEva SA today announced that it intends for its common shares to be traded under a new International Securities Identification Numbers (“ISIN”) beginning on April 25, 2023.

ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s health, published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022.

ObsEva SA announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy.